Comparison
Abeta Amyloidosis Arctic Type C2751494 vs 17q24 2 Microdeletion Syndrome C5680185
Clinical comparison between Abeta Amyloidosis Arctic Type and 17q24 2 Microdeletion Syndrome for differential diagnosis and treatment planning.
Abeta Amyloidosis Arctic Type C2751494
Hereditary amyloidosis from APP gene mutation causing amyloid buildup in brain blood vessels. Runs in families. Managed symptomatically.
17q24 2 Microdeletion Syndrome C5680185
A rare genetic disorder caused by deletion of genetic material on chromosome 17. Individuals may have developmental delays, facial features, and other medical issues. Care is supportive and multidisciplinary.
6 comparison axes
Onset
Abeta Amyloidosis Arctic Type C2751494
50-65
17q24 2 Microdeletion Syndrome C5680185
0-null
Onset patterns differ
Severity
Abeta Amyloidosis Arctic Type C2751494
severe
17q24 2 Microdeletion Syndrome C5680185
moderate
Different severity levels
Chronic
Abeta Amyloidosis Arctic Type C2751494
Chronic
17q24 2 Microdeletion Syndrome C5680185
Chronic
Differing course
Communicable
Abeta Amyloidosis Arctic Type C2751494
No
17q24 2 Microdeletion Syndrome C5680185
No
Different transmission
Body System
Abeta Amyloidosis Arctic Type C2751494
neurologic
17q24 2 Microdeletion Syndrome C5680185
congenital
Same/different system
Category
Abeta Amyloidosis Arctic Type C2751494
rare-disease
17q24 2 Microdeletion Syndrome C5680185
genetic
Different category
Bottom line
abeta-amyloidosis-arctic-type-C2751494 and 17q24-2-microdeletion-syndrome-C5680185 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abeta Amyloidosis Arctic Type C2751494 | 17q24 2 Microdeletion Syndrome C5680185 | Discriminating power |
|---|---|---|---|
| Age at recognition | Typically recognized in adulthood, reported around ages 50–65. | Present from birth or early development; exact onset range is not established. | High |
| Main clinical domain | Neurologic disease related to amyloid in brain blood vessels. | Congenital pattern that may include developmental delay and facial features. | High |
| Family pattern | Hereditary and may run in families through an APP mutation. | Caused by deletion of chromosome 17 material; inheritance pattern is not specified here. | Moderate |
When to favor each condition
Choose Abeta Amyloidosis Arctic Type C2751494 when
Adult-onset progressive neurologic illness in a family
Fits the described hereditary APP-related amyloid process better than a congenital syndrome.
Moderate
Suspected cerebral vascular amyloid disease
The source specifically links Arctic type to amyloid buildup in brain blood vessels.
Moderate
Genetic evaluation targets APP rather than a deletion
The stated etiology is an APP gene mutation, not chromosome 17q24.2 loss.
High
Choose 17q24 2 Microdeletion Syndrome C5680185 when
Congenital or early developmental concerns
The microdeletion is a congenital genetic disorder rather than an adult-onset amyloid disease.
High
Developmental delay with possible characteristic facial features
These features are described for the syndrome, though they are not definitive alone.
Moderate
Chromosomal microarray suggests 17q24.2 material loss
A deletion finding directly supports this diagnosis over APP amyloidosis.
High
How key tests differ
| Test | Abeta Amyloidosis Arctic Type C2751494 | 17q24 2 Microdeletion Syndrome C5680185 | Interpretation |
|---|---|---|---|
| APP gene testing | May identify the disease-associated APP mutation when clinically indicated. | Not the primary test for a chromosomal microdeletion. | A positive APP result supports Arctic-type amyloidosis but does not exclude unrelated findings. |
| Chromosomal microarray | Not expected to establish this APP-related diagnosis. | May detect deletion of 17q24.2 material. | Deletion size and clinical correlation require specialist interpretation. |
| Neurologic assessment | Focused on adult neurologic manifestations of cerebral amyloid disease. | Focused on development and associated congenital medical issues. | Assessment findings suggest a direction but are not diagnostic by themselves. |
Prognosis comparison
Abeta Amyloidosis Arctic Type C2751494
- Outcome
- Described as severe and chronic; survival and functional outcomes are not established here.
- Factors
- Age at onset, neurologic burden, and confirmed APP mutation may matter, but effects are not quantified.
17q24 2 Microdeletion Syndrome C5680185
- Outcome
- Described as moderate and chronic, with variable developmental and medical needs.
- Factors
- Deletion extent, developmental profile, and associated medical issues likely influence needs.
Time frame: Lifelong course; Arctic type is typically recognized in later adulthood, while the deletion is congenital.
Individual prognosis requires specialist assessment and should not be inferred from severity labels alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic progression | Severe chronic neurologic disease is described; exact complications are not established here. Neurologic issues may occur through developmental disability, but a specific course is not established. Do not infer stroke, seizure, or dementia rates from these sparse data. |
| Developmental impairment | Not described as a congenital developmental syndrome. Developmental delays may occur and need individualized support. Severity and affected domains vary and are not quantified here. |
| Multisystem medical needs | Management is described as symptomatic; organ involvement beyond brain vessels is not established. Other medical issues may occur and are managed supportively. Both require clinician-directed surveillance rather than a fixed complication list. |
Patient education highlights
- HighDifferent causes
One condition involves a hereditary APP mutation and brain-vessel amyloid; the other involves missing chromosome 17 material.
- HighCare approach
Arctic type is managed symptomatically; the microdeletion needs supportive, multidisciplinary care.
- MediumLimits of available information
Exact symptoms, test cutoffs, prognosis, and treatment doses are not established by this comparison.